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IntroductIon
Serine Proteases
Serine proteases are proteolytic enzymes. More than 
one third of all known proteolytic enzymes are serine 
proteases. Over 18,000 serine proteases are grouped 
into 12 superfamilies and 40 families. Serine proteas-
es are widely distributed in nature and are found in all 
kinds of living organisms including viral genomes1.
The active site of serine proteases contains three 
critical aminoacids: serine, histidine and aspartate. 
These residues are often referred to as the “catalytic 
triad”2.
Serine proteases play diverse roles in human health, 
from non-specific digestion to highly regulated func-
tions like embryonic development, immune response, 
blood coagulation and facilitation of sperms entering 
the egg1,3.
Serine proteases catalyze peptide bond cleavage 
of attacking substrate in a two-step process. Initially, 
the catalytic serine performs a nucleophilic attack on 
the peptide bond of the substrate. This releases the 
new N-terminus and forms an ester-bond between 
the enzyme and the substrate. This covalent enzyme-
substrate complex is called acylenzyme intermediate. 
Subsequent to this, this ester bond is hydrolysed and 
the new C-terminus is released.
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Serpins
Regulation of protease activity in vivo from endog-
enous factors is critical for body homeostasis4. Such 
processes require timely and tightly regulated prote-
olytic activity. Initiation of protease activity is largely 
controlled by zymogen activation. Cessation of pro-
tease activity is achieved in vivo by endogenous pro-
tease inhibitors1.
Endogenous protease inhibitors are proteins, which 
were initially identified in blood plasma and represent 
> 10% of the total plasma proteins. Among the differ-
ent classes of protease inhibitors in blood plasma, the 
majority is serine protease inhibitors, which appear to 
be involved in various pathways4.
Serine protease inhibitors consist the superfamily 
of serpins (SERPINS: SERine Protease InhibitorS)4,5,6. 
It is important to emphasize that even though all the 
serpins share the same tertiary structure,4 they have 
different functions.
Serpin structure and protease inhibition mechanism
Serpins consist of three β-sheets (A, B and C), 8-9 
α-helices (termed hA-hI) and the reactive center 
known as reactive center loop (RCL), which is re-
sponsible for the interaction with the serpin targets6 
(Figure 1).
The serpin inhibition of protease proceeds via an 
initial formation of a noncovalent and reversible com-
plex, (also known as the Michaelis complex) where 
the sequence of the RCL is recognized by the protease 
as a substrate and there is no conformational change 
within the protease or the body of the serpin. Subse-
quent peptide bond hydrolysis results in an acylen-
zyme intermediate that progresses to either a kinetical-
ly trapped loop-inserted covalent complex (inhibitory 
pathway) or a cleaved serpin and free protease (non 
inhibitory or substrate pathway)7.
The RCL of a serpin acts as a substrate for its 
cognate protease. Indeed, serpins form covalent com-
Figure 1. The structure of the archetypical serpin, α1-Antitrypsin (SERPIN A1)6.
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plexes with target proteases. Prior to hydrolysis of the 
acyl-enzyme intermediate, after the RCL is cleaved, 
the serpin rapidly undergoes the S-to-R transition. 
Since the RCL is still covalently attached to the pro-
tease via the ester bond, the S-to-R transition causes 
the protease to be moved from the top to the bottom of 
the serpin. At the same time, the protease is distorted 
into a conformation, where the acylenzyme interme-
diate is hydrolysed extremely slowly. The protease 
thus remains covalently attached to the target serpin 
and is thereby inhibited. Further, since the serpin has 
to be cleaved to inhibit the target protases, inhibition 
consumes the serpin as well. Serpins are therefore ir-
reversible ‘suicide’ enzyme inhibitors6,7.
Certain serpins spontaneously undergo the S to R 
transition as part of their function, to form a confor-
mation termed the latent state. In latent serpins the 
first strand of the C-sheet has to peel off to allow full 
RCL insertion. Latent serpins are unable to interact 
with proteases and are not protease inhibitors. The 
transition to latency represents a control mechanism 
for the serpin PAI-16.
Proteolytic cleavage of the serpins can result in a 
much more stable protein with new biological prop-
erties, including their chemo-attractant behavior. 
These structural transformations of serpins provide 
opportunities for regulation of the activity and proper-
ties of the inhibitor and are likely important in vivo 
in the regulation of processes like immunoregula-
tion, cell migration, cell apoptosis control, blood co-
agulation and fibrinolysis, complement activation and 
inflammation8,9.
The primary function of most serpins is the regula-
tion of proteolysis by inhibition and this affects many 
biochemical pathways. However, many serpins have 
alternative, non-inhibitory functions, such as hormone 
transport (cortisol-binding globulin and thyroxine 
binding globulin)10,11, blood pressure regulation12 and 
tumor suppression8. The function of serpins is either 
intracellular or extracellular. Changes in the structure 
of the serpin molecule, especially of the active center, 
or deficient synthesis, can lead to pathologic condi-
tions, collectively termed serpinopathies13.
Serpins and obesity 
Human serpins are involved in diverse biologic func-
tions. For some serpins, their biologic functions ap-
pear to be directly related to protease inhibition. The 
large number of serpins, their ubiquitous presence in 
different organisms (e.g. metazoan, plantae and vi-
ruses) and the great variety of biological functions in 
which they are involved (Figure 2)4, raise substantial 
research interest.
The multiple regulatory functions of serpins (Fig-
ure 2) and especially their participation in inflam-
matory processes and in fibrinolysis and coagulation 
Figure 2. Regulatory functions of serpins4.
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cascades, in which obesity is involved, lead to the 
investigation of the relationship between serpins and 
obesity.
Adipose tissue has long been overlooked in terms 
of its physiological impact and was considered only 
as a passive energy store in the form of fat. How-
ever, it is now clear that the adipose tissue is a ma-
jor source for many factors, which link obesity with 
many different associated diseases14. Adipose tissue 
is currently considered an organ that not only stores 
energy but also acts as a multifunctional endocrine 
tissue, that expresses and secretes a variety of bioac-
tive peptides, known as “adipokines”, which act at 
both the local (autocrine-paracrine) and the systemic 
(endocrine) level15. Τhe adipokines regulate systemic 
processes, including food intake and nutrient metabo-
lism, insulin sensitivity, stress responses, reproduc-
tion, bone growth and inflammation16. Similarly, adi-
pokines contribute to the pathogenesis of endothelial 
dysfunction, dyslipidemia and impaired coagulation. 
Perturbed adipokine secretion affects the function of 
various organs and results in many different metabolic 
disorders14,15,16.
Many adipokines have been identified, including 
leptin, adiponectin, visfatin, tumor necrosis factor-a 
(TNF-α), interleukin-6 (IL-6), plasminogen activator 
inhibitor-1 (ΡΑΙ-1)15, C-reactive protein (CRP)17,18.
It is important to stress that there are serpins that 
belong to the fibrinolytic system. The best known ser-
pin of this system is PAI-1 (SERPIN E1). Other ex-
amples of serpins that inhibit proteases involved in the 
generation and control of plasmin function are PAI-2 
(SERPIN B2) and α2-antiplasmin (SERPIN F2)19. 
ΡΑΙ-1 is a major regulator of the fibrinolytic system, 
i.e. the natural defense mechanism against thrombo-
sis. The major sources of PAI-1 synthesis are hepa-
tocytes and endothelial cells, but platelets, smooth 
muscle cells, and adipocytes also produce PAI-120. 
The increased gene expression and secretion of PAI-1 
by adipose tissue contribute to the elevated plasma 
PAI-1 levels in obesity, which strongly correlate with 
features of the insulin resistance syndrome, namely 
elevated fasting plasma insulin and triglyceride lev-
els, high BMI, and visceral fat accumulation. Both the 
levels and the functional impact of ΡΑΙ-1 are affected 
by adipose tissue mass. ΡΑΙ-1 levels are also influ-
enced from various metabolic disturbances including 
the metabolic syndrome and type 2 diabetes mellitus, 
conditions that are associated with increased adipose 
tissue mass21,22. This increase is associated with up-
regulated PAI-1 gene expression, which results in 
increased plasma PAI-1 levels. Moreover, in patients 
with visceral obesity, PAI-1 is implicated in the patho-
genesis of cardiovascular disease23,24. The cardinal 
feature in all the afore-mentioned diseases is insulin 
resistance, which is induced by the increase in visceral 
adipose tissue mass25.
Adipose tissue-induced insulin resistance 
Insulin resistance and the compensatory hyperinsuli-
naemia, which are induced by the increase in adipose 
tissue mass, are considered important contributors to 
the biological and metabolic disturbances observed in 
obesity. A variety of molecules, including free fatty 
acids, TNF-α26, leptin27, adiponectin and resistin play 
a role in the pathogenesis of obesity and its associ-
ated diseases, e.g. type 2 diabetes mellitus. In type 2 
diabetes mellitus, adipokines modify insulin sensitiv-
ity in peripheral tissues. The activation of adipokine 
excretion triggers multiple reactions, following the 
insulin receptor phosphorylation, while in the same 
time adipokines activate other molecules28 which 
exert endocrine actions in various target tissues, in-
cluding muscles, liver and hypothalamus. Some adi-
pokines (e.g. TNF-α, IL-6 and resistin) induce insu-
lin resistance and inflammation whereas others (e.g. 
leptin and adiponectin) are considered necessary for 
glucose homeostasis and energy control29. TNF-α, 
IL-6, resistin and PAI-1 contribute to the pathogenesis 
of obesity-related metabolic disorders and finally to 
atherothrombosis29.
Vaspin: a new adipokine that belongs to the serpin su-
perfamily
To assess the relationship between obesity and insu-
lin resistance, various experimental models are being 
used, particularly the Otsuka Long-Evans Tokushima 
fatty rats (OLETF rats), which comprise a genetic 
model of type 2 diabetes mellitus. These rats are 
characterized by visceral obesity, insulin resistance, 
hyperinsulinemia, hyperglycemia, hypertension and 
dyslipidemia30. The OLETF rats are being compared 
with their diabetes-resistant counterparts, the Long-
Evans Tokushima Otsuka rats (LETO rats), which are 
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characterized by a minimal volume of omental fat, 
absence of insulin resistance and no development of 
type 2 diabetes mellitus. In these experiments, various 
tissue samples (from brain, heart, lung, spleen, kid-
ney, small intestine, muscle, brown adipose tissue and 
subdermal adipose tissue) were harvested from both 
rat strains31. In the harvested tissue, gene isolation 
and identification was performed. Among the genes 
upregulated in the visceral adipose tissue of OLETF 
rats, ten known and three novel genes were isolated. 
Some of these genes showed visceral adipose tissue-
specific expression and were not detected in neither 
subcutaneous nor brown adipose tissue31.
The isolated genes were classified into three groups: 
the first group comprised of known genes with iden-
tified functions. Some of these had already been re-
ported to be upregulated in situations of increased vis-
ceral adipose tissue [enzymes related to glucose and 
lipid metabolism including lipoprotein lipase (LPL), 
phosphoenol-pyruvate carboxykinase (PEPCK), cho-
lesterol esterase (CE) and c-Cbl-associated protein 
(CAP)]. The second group comprised of known genes 
with unknown function in the adipose tissue (nucleo-
lar phosphoprotein of 140 kDa (Nopp140), trans-Golgi 
network 38 (TGN 38), selenoprotein P, thrombospon-
din 1 and contrapsin-like protease inhibitor). The third 
group comprised of three new, uncharacterized genes, 
which were exclusively expressed in the visceral adi-
pose tissue of OLETF rats.
Among these novel genes, OL-64 was exclusively 
expressed in the visceral adipose tissue of OLETF rats 
and was not identified in brown adipose tissue or in 
subcutaneous adipose tissue, neither in any other or-
gan32. The study of the aminoacid sequence of the OL-
64 gene revealed a 40% homology with antitrypsin. 
The gene product of OL-64 is a novel member of the 
serine protease inhibitor (serpin) gene family and was 
named vaspin (Visceral Adipose tissue-derived Ser-
PIN). The gene that encodes for vaspin has a molecu-
lar size of 1.8 kbs31 and maps on the chromosome 14 
(14q32.13). The structure of vaspin molecule follows 
the characteristic serpin structure and consists of three 
β-sheets (Α, Β, C), nine α-helices, and one active site 
loop (Figure 3).
After isolating and cloning vaspin molecule, it was 
revealed that vaspin cDNA consists of 1236, 1242 and 
1245 nucleotides in rats, mice and humans, respec-
tively. The corresponding proteins consist of 412, 414, 
and 415 aminoacids, respectively32.
Discovery, isolation, cloning and identification of 
vaspin was followed by intensive research on the bio-
logical actions of this adipokine32.
Vaspin levels and biological actions in experimental 
models
Vaspin was identified in the serum of both OLETF 
and LETO rats. The vaspin serum levels are higher in 
OLETF rats than LETO rats during the period of max-
imal insulin resistance. In OLETF rats, vaspin serum 
levels significantly decline when these rats developed 
severe hyperglycemia. In turn, treatment with insulin 
and thiazolidinediones (TZD) increase serum vaspin 
levels in OLETF rats.
Experimental studies in the Imprinting Control Re-
gion (ICR) mice suggest that vaspin sensitizes periph-
eral tissues to insulin action. ICR mice do not develop 
obesity when fed a normal diet but when they are fed 
a lipid- and sucrose-enriched diet develop obesity, hy-
perinsulinemia and hyperglycemia, which resembles 
metabolic syndrome.
Figure 3. The molecular structure of vaspin32.
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Administration of recombinant vaspin (rh-vaspin) 
in these obese, hyperinsulinemic and hyperglycemic 
ICR mice reduced significantly their glucose levels, 
120 minutes after the intraperitoneal injection of glu-
cose, while insulin levels were not altered. This result 
suggests sensitization of peripheral tissues to insulin 
action by vaspin, which attenuates insulin resistance 
in these diet-induced obese mice.
Recombinant vaspin administration also sup-
pressed the expression of leptin, resistin and TNF-α 
whereas it increased the expression of adiponectin 
and glucose transporter-4, suggesting that vaspin ad-
ministration down-regulates the expression of insulin 
resistance-promoting genes.32. Therefore, it appears 
that vaspin improves the insulin sensitivity of periph-
eral tissues by modulating gene expression, mainly in 
visceral and subcutaneous white adipose tissue.
In conclusion, vaspin is a novel adipokine that be-
longs to serpins and is expressed mainly in the vis-
ceral white adipose tissue but is also present in serum. 
Obesity and insulin resistance increase both vaspin 
expression in the visceral adipose tissue and serum 
vaspin levels, whereas the latter decline as diabetes 
worsens in rats. Administration of insulin and TZD 
up-regulate vaspin expression in the adipose tissue 
and serum vaspin levels. This up-regulation of vaspin 
synthesis might represent a compensatory response 
to antagonize the action of yet-unknown proteases 
derived from fat or other tissues, which antagonize 
insulin action. Therefore, the up-regulation of vaspin 
expression might constitute a defense mechanism 
against insulin resistance. Administration of rh-vaspin 
in rats suppressed gene expression of the adipokines 
leptin, resistin, and TNF-α, which increase the resis-
tance of peripheral tissues to insulin, and increased the 
expression of glucose transporter-4 and adiponectin, 
which ameliorate insulin resistance. These findings 
support the hypothesis that vaspin down-modulates 
the expression of genes related to insulin resistance, 
normalizing their expression mainly in adipose tis-
sue32.
Vaspin levels and biological actions in humans
The expression of vaspin mRNA in obese humans cor-
relates with adipose tissue mass, while vaspin mRNA 
is not detectable in lean humans with normal glucose 
tolerance. These findings indicate that the expression 
of vaspin mRNA in the adipose tissue is regulated 
in a fat depot-specific manner and could represent a 
compensatory response associated with obesity, insu-
lin resistance and type 2 diabetes mellitus33. It there-
fore appears that vaspin is a new marker of obesity 
and impaired insulin sensitivity. At present, there is 
no clear proof of a causal link between vaspin levels 
and visceral fat accumulation or insulin resistance34. 
However, it has been shown that vaspin levels are also 
gender-dependent, since women have significantly 
higher vaspin levels compared to men35. Women with 
normal glucose tolerance have vaspin levels up to 
2.5 times higher than men36. A recent study showed 
that serum vaspin levels present a meal-related diur-
nal variation37. Serum vaspin levels show a prepran-
dial rise, 1-2 hours before the beginning of the meal. 
The higher levels were observed before lunch and the 
lowest before breakfast. Postprandially, vaspin lev-
els decline gradually to preprandial levels within 2 
hours after meal. Vaspin concentration also showed a 
nocturnal rise, with a peak at nighttime, when vaspin 
levels were approximately 250% higher than lowest 
daytime levels. This diurnal variation of serum vaspin 
concentration was exactly reciprocal to that of insulin 
and glucose variation. Insulin levels increase 4.7-8.3 
times within thirty minutes after the beginning of the 
meal and gradually decline postprandially to reach 
preprandial levels before the next meal. In addition, 
insulin levels remain low during sleep37.
It has been observed that serum vaspin concentra-
tion is exactly reciprocal to insulin levels37. In contrast, 
in other studies; insulin administration in OLETF rats 
resulted in an increase in serum vaspin levels but did 
not affect vaspin excretion in adipose cell culture, 
suggesting that insulin does not regulate vaspin gene 
expression through a direct action on adipose cells32.
Vaspin in the polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is one of the com-
monest endocrine disorders in women of reproductive 
age and the commonest cause of anovulatory infer-
tility in western countries. The commonest clinical 
manifestations of PCOS are menstrual irregularity 
(because of anovulation) and signs of hyperandrogen-
emia, including hirsutism, seborrhoea, acne and an-
drogenic alopecia38.
Women with PCOS frequently exhibit insulin re-
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sistance34 and obesity, with 38-88% of women with 
PCOS being overweight or obese39,40. The majority of 
women with PCOS, irrespective of their body weight, 
develop a particular type of insulin resistance, which 
is characteristic of the syndrome and of incompletely 
understood pathogenesis41,42,43.
Given that 1) women with PCOS have hyperinsu-
linemia independently of obesity, 2) hyperinsulinemia 
is not a feature of hyperandrogenic states in general, 
3) only obese PCOS women are at risk for impaired 
glucose tolerance, and 4) PCOS is associated with a 
unique type of insulin resistance, it appears that the 
adverse effects of PCOS and obesity on insulin action 
are additive or synergistic42.
All PCOS women are at risk for insulin resistance 
and the associated metabolic abnormalities of the in-
sulin resistance syndrome (dyslipidemia, impaired 
fibrinolysis, cardiovascular disease, hypertension, 
gestational and type 2 diabetes mellitus (GDM)44. In-
deed, in the United States, the prevalence of type 2 
diabetes mellitus is 10 times higher in young women 
with PCOS than in age-matched controls43. Moreover, 
30-50% of obese women with PCOS after the age of 
30 years develop impaired glucose tolerance or type 2 
diabetes mellitus45,46,47.
The diagnostic criteria that have been proposed for 
PCOS have been revised by the Rotterdam ESHRE/
ASRM-Sponsored PCOS Consensus Workshop 
Group48,49. According to this expert group, PCOS is 
diagnosed - after the exclusion of related disorders - 
when two of the following three features are present: 
1) oligo- or anovulation, 2) clinical signs and/or bio-
chemical hyperandrogenism, or 3) polycystic ovaries 
on ultrasound. After adding this third criterion, i.e. 
polycystic ovarian morphology in ultrasound, there 
are four phenotypes of PCOS (Table 1).
According to the National Institutes of Health 
(NIH) criteria proposed in April of 1990, PCOS was 
diagnosed when both hyperandrogenism and/ or hy-
perandrogenemia and oligoovulation or anovulation 
were present50.
These two major definitions of PCOS are the sub-
ject of intense controversy51,52 and this impacts both 
clinical diagnosis and research52.
Lately, the Androgen Excess Society, in a position 
statement, defined PCOS as a predominantly hyperan-
drogenic syndrome and concluded that PCOS should 
first be considered as a disorder of androgen excess 
or hyperandrogenism (disorder in biosynthesis, use or 
metabolism of androgens)53. Thus, ovulatory hyper-
androgenic women with polycystic ovaries on ultra-
sound examination (phenotype 3, Table 1) exhibit a 
mild form of the syndrome. Chronic oligo- or anovu-
latory women with polycystic ovaries on ultrasound 
examination also constitute a mild form of PCOS54 
(phenotype 4, Table 1), and their metabolic character-
istics are considered too mild or without risk of devel-
oping any metabolic disorder, which are characteristic 
of women with PCOS55,56.
Many patients with polycystic ovary syndrome 
(PCOS) have insulin resistance, obesity (mostly vis-
ceral), glucose intolerance and abnormalities in the 
table 1. The four phenotypes of polycystic ovary syndrome (PCOS) according to the revised diagnostic criteria proposed 
by the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group48,49.
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secretion of steroid hormones from the ovaries and 
the adrenal gland, conditions associated with abnor-
malities in the production of vaspin. Accordingly, re-
cent studies evaluated vaspin levels in women with 
PCOS.
Currently, there are only four studies that assessed 
serum vaspin levels in women with PCOS with contro-
versial results. The first study included a small number 
of subjects (12 women with PCOS and 12 controls)57. 
Serum vaspin levels were evaluated and vaspin gene 
(mRNA) expression was determined in both subcuta-
neous and omental adipose tissue in vitro. Addition-
ally, the effects of glucose, insulin and steroid hor-
mone administration on vaspin gene expression and 
on vaspin levels in the adipose tissue were examined. 
Moreover, the effects of metformin treatment on se-
rum vaspin levels and on clinical, hormonal and met-
abolic features of PCOS were evaluated. This study 
reported: a) higher serum vaspin levels in women with 
PCOS than in controls (p < 0.05), b) increased vaspin 
mRNA and vaspin levels in the omental adipose tissue 
of PCOS women (p < 0.05) and increase (p < 0.001) 
in vaspin protein levels and secretion into conditioned 
media after adding glucose to omental adipose tissue 
explants and c) a significant decrease in serum vaspin 
levels in PCOS women after six months of metformin 
treatment (p < 0.001).
Similar results, i.e. decreased vaspin levels, were 
reported in female diabetic patients, who were receiv-
ing metformin compared with matched controls58. In 
addition, female patients with glycosylated hemoglo-
bin (HbA1c) levels > 7% had higher serum vaspin lev-
els than patients with HbA1c levels < 7%. Thus, the 
impaired glucose regulation in diabetic patients is as-
sociated with increased serum vaspin levels. Addition-
ally, decreased serum vaspin levels were reported in 
female patients with microangiopathy (diabetic retin-
opathy, nephropathy and neuropathy). In contrast, in 
non diabetic subjects, serum vaspin levels did not cor-
relate with indices of insulin sensitivity59.
The second study60 of vaspin levels in PCOS in-
cluded a larger number of PCOS women and controls 
(42 PCOS women and 42 obese nonhyperandrogenic 
women; 26 subjects were severely obese, 15 with 
PCOS). Serum vaspin levels were determined in all 
women. In addition, serum vaspin levels were evalu-
ated in the 26 severely obese patients after bariatric 
surgery and in 34 PCOS patients after treatment with 
either metformin (n = 19) or an antiandrogenic oral 
contraceptive pill (n = 15). In this study, serum vaspin 
concentration was not significantly influenced by PCOS 
or obesity. Circulating vaspin levels were also similar 
in women with normal or impaired glucose tolerance. 
After bariatric surgery, which resulted in significant 
weight loss and reduction in waist circumference, se-
rum vaspin levels decreased significantly, irrespective 
of the presence or absence of PCOS. Moreover, serum 
vaspin levels decreased slightly after treatment with 
metformin for 24 months and increased significantly 
in women treated with oral contraceptives. The au-
thors concluded that the change in vaspin levels might 
represent a compensatory mechanism against insulin 
resistance and glucose intolerance.
In the third study61 serum vaspin levels were deter-
mined in 24 patients with PCOS, in 23 women with 
polycystic ovaries (PCO) and in 24 controls. Patients 
with PCOS or PCO had higher serum vaspin levels 
than controls.
We recently reported our findings in 79 patients 
with PCOS and 50 healthy female volunteers62. Nor-
mal weight patients with PCOS (n = 25) were treated 
with metformin 850 mg bid for 6 months. Overweight/ 
obese patients with PCOS (n = 54) were prescribed a 
normal-protein, energy-restricted diet for 6 months; 
half of them were also given orlistat 120 mg tid and the 
rest were given sibutramine 10 mg qd. At baseline and 
after 6 months, serum vaspin levels and anthropomet-
ric, metabolic and hormonal features of PCOS were 
determined. Overall, patients with PCOS had higher 
vaspin levels than controls (p = 0.021). Normal weight 
patients with PCOS had higher vaspin levels than nor-
mal weight controls (p = 0.043). Vaspin levels were 
non-significantly higher in overweight/ obese patients 
with PCOS than in overweight/obese controls. In nor-
mal weight patients with PCOS, metformin reduced 
vaspin levels non-significantly. In overweight/ obese 
patients with PCOS, diet plus orlistat or sibutramine 
did not affect vaspin levels. Vaspin levels were inde-
pendently correlated with body mass index in women 
with PCOS (p = 0.001) and with waist circumference 
in controls (p = 0.015). In conclusion, our results sug-
gest that serum vaspin levels are elevated in PCOS 
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but neither a small weight loss, nor metformin affect 
vaspin levels significantly.
As a conclusion, current data on serum vaspin lev-
els in PCOS women are controversial and there is a 
need for additional larger studies to elucidate the role 
of vaspin in PCOS.
ΠΕΡΙΛΗΨΗ: Το 2000 απομονώθηκε από το σπλαγχνικό λιπώδη ιστό μία νέα λιποκίνη, που ανήκει στην υπεροικογένεια των 
σερπινών, η βασπίνη. Η βασπίνη παράγεται, ενδεχομένως, από το σπλαγχνικό λιπώδη ιστό και σχετίζεται με την αντίσταση 
στην ινσουλίνη, τα επίπεδα του σακχάρου, τις ορμόνες, το φύλο (υψηλότερες τιμές στις γυναίκες από τους άνδρες) και τη 
διατροφή. Επιπλέον, επηρεάζεται από την απώλεια βάρους και τη λήψη φαρμάκων. Έτσι, η βασπίνη φαίνεται να συνδέει την 
παχυσαρκία με τις μεταβολικές της επιπτώσεις στον άνθρωπο. Έχει, μάλιστα, αναφερθεί ότι η λιποκίνη αυτή θα μπορούσε να 
θεωρηθεί ένας καινούργιος βιο-δείκτης για την παχυσαρκία και την αντίσταση στην ινσουλίνη. Πρέπει, πάντως, να σημειωθεί 
ότι στις διάφορες μελέτες τα ευρήματα είναι αντικρουόμενα, γεγονός που καθιστά ελκυστικό και αναγκαίο τον περαιτέρω 
έλεγχο της βασπίνης σε διάφορες παθολογικές καταστάσεις, όπως το σύνδρομο των πολυκυστικών ωοθηκών. 
Λέξεις Κλειδιά: Βασπίνη, Σερπίνη, Παχυσαρκία, Αντίσταση στην ινσουλίνη, Σύνδρομο πολυκυστικών ωοθηκών.
Βασπίνη: μια νέα λιποκίνη, μέλος της οικογένειας των αναστολέων  
των πρωτεασών της σερίνης.
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